ARK Genomic Revolution ETF Newsroom

JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating

MT NewswiresJul 15 10:37 ET

Nurix Therapeutics Analyst Ratings

BenzingaJul 15 10:03 ET

Barclays Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)

TipRanksJul 14 21:39 ET

Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating

MT NewswiresJul 12 10:20 ET

Nurix Therapeutics (NRIX) Receives a Buy From Wells Fargo

TipRanksJul 12 09:00 ET

Morgan Stanley Reaffirms Their Hold Rating on Ionis Pharmaceuticals (IONS)

TipRanksJul 12 08:40 ET

Piper Sandler Remains a Buy on Nurix Therapeutics (NRIX)

TipRanksJul 12 06:38 ET

Nurix Therapeutics Analyst Ratings

BenzingaJul 12 06:14 ET

Stifel Nicolaus Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

TipRanksJul 11 09:25 ET

Recursion Pharmaceuticals Analyst Ratings

BenzingaJul 11 07:03 ET

Schrodinger Analyst Ratings

BenzingaJul 11 06:59 ET

Nephron Initiates CareDx at Hold Rating With $15 Price Target

MT NewswiresJul 10 07:58 ET

Twist Bioscience Analyst Ratings

BenzingaJul 9 10:47 ET

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)

TipRanksJul 9 10:08 ET

Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target

MT NewswiresJul 9 07:42 ET

Schrodinger Analyst Ratings

BenzingaJul 2 13:02 ET

Twist Bioscience Analyst Ratings

BenzingaJun 28 12:03 ET

Nurix Therapeutics Analyst Ratings

BenzingaJun 27 10:30 ET

Intellia Therapeutics Analyst Ratings

BenzingaJun 27 09:38 ET

Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target

BenzingaJun 27 09:38 ET